{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T09:41:54Z","timestamp":1770975714533,"version":"3.50.1"},"reference-count":8,"publisher":"Springer Science and Business Media LLC","issue":"3-4","license":[{"start":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T00:00:00Z","timestamp":1755475200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T00:00:00Z","timestamp":1755475200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Wien Klin Wochenschr"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s00508-025-02583-x","type":"journal-article","created":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T08:01:46Z","timestamp":1755504106000},"page":"121-123","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["When rash challenges treatment: reintroducing cystic fibrosis modulator therapy safely"],"prefix":"10.1007","volume":"138","author":[{"given":"T.","family":"Vuki\u0107 Bili\u0107","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Alebi\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Bani\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Darapi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Liki\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Ganza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Rnjak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Tje\u0161i\u0107-Drinkovi\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1522-3325","authenticated-orcid":false,"given":"A.","family":"Vuki\u0107 Dugac","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,8,18]]},"reference":[{"issue":"12","key":"2583_CR1","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1164\/rccm.202102-0509OC","volume":"203","author":"ET Zemanick","year":"2021","unstructured":"Zemanick\u00a0ET, Taylor-Cousar\u00a0JL, Davies\u00a0J, Gibson\u00a0RL, Mall\u00a0MA, McKone\u00a0EF, et\u00a0al. A\u00a0Phase\u00a03 Open-Label Study of Elexacaftor\/Tezacaftor\/Ivacaftor in Children 6 through 11 Years of Age with Cystic Fibrosis and at Least One F508del Allele. Am J Respir Crit Care Med. 2021;203(12):1522\u201332. https:\/\/doi.org\/10.1164\/rccm.202102-0509OC.","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"2583_CR2","doi-asserted-by":"publisher","first-page":"463","DOI":"10.5863\/1551-6776-27.5.463","volume":"27","author":"ER Diseroad","year":"2022","unstructured":"Diseroad\u00a0ER, Mogayzel\u00a0PJ Jr, Pan\u00a0A. Rechallenge of Elexacaftor\/Tezacaftor\/Ivacaftor After Skin Rash in Two Pediatric Patients. J\u00a0Pediatr Pharmacol Ther. 2022;27(5):463\u20136. https:\/\/doi.org\/10.5863\/1551-6776-27.5.463.","journal-title":"J Pediatr Pharmacol Ther"},{"issue":"3","key":"2583_CR3","doi-asserted-by":"publisher","first-page":"192","DOI":"10.5863\/1551-6776-25.3.192","volume":"25","author":"K Ridley","year":"2020","unstructured":"Ridley\u00a0K, Elexacaftor-Tezacaftor-Ivacaftor\u00a0CM. The First Triple-Combination Cystic Fibrosis Transmembrane Conductance Regulator Modulating Therapy. J\u00a0Pediatr Pharmacol Ther. 2020;25(3):192\u20137. https:\/\/doi.org\/10.5863\/1551-6776-25.3.192.","journal-title":"J Pediatr Pharmacol Ther"},{"issue":"10212","key":"2583_CR4","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","volume":"394","author":"HGM Heijerman","year":"2019","unstructured":"Heijerman\u00a0HGM, McKone\u00a0EF, Downey\u00a0DG, Van Braeckel\u00a0E, Rowe\u00a0SM, Tullis\u00a0E, et\u00a0al. Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a\u00a0double-blind, randomised, phase\u00a03\u00a0trial. Lancet. 2019;394(10212):1940\u20138. https:\/\/doi.org\/10.1016\/S0140-6736(19)32597-8.","journal-title":"Lancet"},{"issue":"3","key":"2583_CR5","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1164\/rccm.202008-3176LE","volume":"203","author":"M Griese","year":"2021","unstructured":"Griese\u00a0M, Costa\u00a0S, Linnemann\u00a0RW, Mall\u00a0MA, McKone\u00a0EF, Polineni\u00a0D, et\u00a0al. Safety and Efficacy of Elexacaftor\/Tezacaftor\/Ivacaftor for 24\u00a0Weeks or Longer in People with Cystic Fibrosis and One or More F508del Alleles: Interim Results of an Open-Label Phase\u00a03 Clinical Trial. Am J Respir Crit Care Med. 2021;203(3):381\u20135. https:\/\/doi.org\/10.1164\/rccm.202008-3176LE.","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"2583_CR6","doi-asserted-by":"publisher","first-page":"467","DOI":"10.5863\/1551-6776-27.5.467","volume":"27","author":"I Loyd","year":"2022","unstructured":"Loyd\u00a0I, Papac\u00a0N, Hirshburg\u00a0J, Levin\u00a0J, Dannelley\u00a0J, Dorris\u00a0J, et\u00a0al. If At First You Don\u2019t Succeed, Trikafta Again. J\u00a0Pediatr Pharmacol Ther. 2022;27(5):467\u20139. https:\/\/doi.org\/10.5863\/1551-6776-27.5.467.","journal-title":"J Pediatr Pharmacol Ther"},{"issue":"3","key":"2583_CR7","doi-asserted-by":"publisher","first-page":"e247042","DOI":"10.1136\/bcr-2021-247042","volume":"15","author":"A Cheng","year":"2022","unstructured":"Cheng\u00a0A, Baker\u00a0O, Hill\u00a0U. Elexacaftor, tezacaftor and ivacaftor: a\u00a0case of severe rash and approach to desensitisation. BMJ Case Rep. 2022;15(3):e247042\u20132. https:\/\/doi.org\/10.1136\/bcr-2021-247042.","journal-title":"BMJ Case Rep"},{"issue":"6","key":"2583_CR8","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1016\/j.jcf.2022.05.001","volume":"21","author":"G Spoletini","year":"2022","unstructured":"Spoletini\u00a0G, Gillgrass\u00a0L, Pollard\u00a0K, Shaw\u00a0N, Williams\u00a0E, Etherington\u00a0C, et\u00a0al. Dose adjustments of Elexacaftor\/Tezacaftor\/Ivacaftor in response to mental health side effects in adults with cystic fibrosis. J\u00a0Cyst Fibros. 2022;21(6):1061\u20135. https:\/\/doi.org\/10.1016\/j.jcf.2022.05.001.","journal-title":"J Cyst Fibros"}],"container-title":["Wiener klinische Wochenschrift"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-025-02583-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00508-025-02583-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-025-02583-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T08:36:09Z","timestamp":1770971769000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00508-025-02583-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,18]]},"references-count":8,"journal-issue":{"issue":"3-4","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["2583"],"URL":"https:\/\/doi.org\/10.1007\/s00508-025-02583-x","relation":{},"ISSN":["0043-5325","1613-7671"],"issn-type":[{"value":"0043-5325","type":"print"},{"value":"1613-7671","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,18]]},"assertion":[{"value":"26 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"T.\u00a0Vuki\u0107 Bili\u0107, M.\u00a0Alebi\u0107, M.\u00a0Bani\u0107, D.\u00a0Darapi, R.\u00a0Liki\u0107, M.\u00a0Ganza, D.\u00a0Rnjak, D.\u00a0Tje\u0161i\u0107-Drinkovi\u0107 and A.\u00a0Vuki\u0107 Dugac declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}